Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas

被引:32
作者
Pott, C
Tiemann, M
Linke, B
Ott, MM
von Hofen, M
Bolz, I
Hiddemann, W
Parwaresch, R
Kneba, M
机构
[1] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany
[2] Inst Hematoopathol, Kiel, Germany
[3] Inst Pathol, Wurzburg, Germany
关键词
mantle cell lymphoma; PCR; bcl-1; IgH-CDR3; sequencing; gene scanning;
D O I
10.1038/sj.leu.2401172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mantle cell lymphoma represent a clinicopathologically distinct entity of malignant non-Hodgkin's lymphoma (NHL) and are characterized by a specific chromosomal translocation t(11;14)(q13;q32) involving the cyclin D1 gene also designated as bcl-1/PRAD1 gene on chromosome 11 and the heavy chain immunoglobulin joining region on chromosome 14. We have established a PCR method to amplify t(11;14) junctional sequences in DNA from fresh frozen and paraffin-embedded tissue by bcl-1-specific primers in combination with a consensus immunoglobulin J(H) primer. A total of 65 cases histologically classified as mantle cell lymphoma (MCL) were analyzed for the presence of a t(11;14) translocation and monoclonal IgH-CDR3 rearrangements. From 26 patients with classical MCL and three cases with the anaplastic variant of MCL fresh frozen biopsy material was available for DNA extraction. We detected a bcl-1/J(H) rearrangement in 12 out of 29 samples (41%). In 36 cases paraffin-embedded lymph node tissue was the only source of DNA. In this material we found a bcl-1/J(H) rearrangement in six out of 31 samples with intact DNA (20%). To confirm the specificity of the PCR and to determine the bcl-1/J(H) junctional region sequences as clone-specific marker in individual patients we characterized the junctional DNA sequences by direct PCR sequencing in 16 cases. Interestingly we found that six bcl-1/J(H) junctions harbored D-H segments in their N regions indicating that bcl-1/J, rearrangements can occur in a later stage of B cell ontogeny during which the complete V-H to D-H-J(H) joining or V-H-replacement takes place. To investigate the suitability of IgH-CDR3 as sensitive molecular marker far those MCL patients in which a t(11;14) translocation can not easily be amplified, we additionally analysed 60 cases for the presence of monoclonally rearranged IgH genes by IgH-CDR3-PCR. A monoclonal IgH-CDR3 PCR product could be identified in 24 out of 29 fresh frozen samples (79%) whereas only 11 out of 31 samples (36%) with paraffin derived DNA were positive. We demonstrate that automated fluorescence detection of monoclonal IgH-CDR3 PCR products allows the rapid and sensitive monitoring of minimal residual disease also in cases that lack a PCR amplifiable t(11;14) translocation. In combination with allele-specific primers the procedure may improve current experimental approaches for detection of occult MCL cells at initial staging and residual disease during and after therapy.
引用
收藏
页码:1630 / 1637
页数:8
相关论文
共 36 条
[1]   Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease [J].
Andersen, NS ;
Donovan, JW ;
Borus, JS ;
Poor, CM ;
Neuberg, D ;
Aster, JC ;
Nadler, LM ;
Freedman, AS ;
Gribben, JG .
BLOOD, 1997, 90 (10) :4212-4221
[2]   Mantle cell lymphoma: A clinicopathologic study of 80 cases [J].
Argatoff, LH ;
Connors, JM ;
Klasa, RJ ;
Horsman, DE ;
Gascoyne, RD .
BLOOD, 1997, 89 (06) :2067-2078
[3]   Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting [J].
Corradini, P ;
Astolfi, M ;
Cherasco, C ;
Ladetto, M ;
Voena, C ;
Caracciolo, D ;
Pileri, A ;
Tarella, C .
BLOOD, 1997, 89 (02) :724-731
[4]  
COTTER F, 1990, BLOOD, V76, P131
[5]  
ELGAVISH RA, 1993, BIOTECHNIQUES, V15, P1066
[6]   High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission [J].
Freedman, AS ;
Neuberg, D ;
Gribben, JG ;
Mauch, P ;
Soiffer, RJ ;
Fisher, DC ;
Anderson, KC ;
Andersen, N ;
Schlossman, R ;
Kroon, M ;
Ritz, J ;
Aster, J ;
Nadler, LM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :13-18
[7]   IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA [J].
GRIBBEN, JG ;
FREEDMAN, AS ;
NEUBERG, D ;
ROY, DC ;
BLAKE, KW ;
WOO, SD ;
GROSSBARD, ML ;
RABINOWE, SN ;
CORAL, F ;
FREEMAN, GJ ;
RITZ, J ;
NADLER, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) :1525-1533
[8]  
Haas R, 1996, BONE MARROW TRANSPL, V17, P149
[9]  
HARRIS NL, 1994, BLOOD, V84, P1361
[10]  
JIANG W, 1993, P NATL ACAD SCI USA, V9, P926